Last reviewed · How we verify
Clevidipine butyrate
Clevidipine butyrate, marketed by Methodist Healthcare, is a drug with a key composition patent expiring in 2028. The drug's market position and primary indication are not specified, but its key strength lies in its unique mechanism of action, which differentiates it from competitors. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | Clevidipine butyrate |
|---|---|
| Also known as | Cleviprex |
| Sponsor | Methodist Healthcare |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Assessment of Efficacy, Safety and Dosing of Clevidipine in Pediatric Participants Undergoing Surgery (PIONEER) (PHASE4)
- a Study Evaluating the Safety and Efficacy of Clevidipine for Patients Who With Hypertensive Emergency and Sub-emergency (PHASE3)
- A Study of Clevidipine Butyrate Injectable Emulsion in the Treatment of Hypertensive Emergency and Sub-emergency (PHASE3)
- Safety and Efficacy Study of Clevidipine to Control Hypertension in Patients Admitted With Aneurysmal Subarachnoid Hemorrhage (PHASE2)
- Clinical Study of Clevidipine Butyrate Injection in the Treatment of Hypertensive Emergency and Sub-emergency (PHASE3)
- Safety and Efficacy Study of Clevidipine Butyrate Injection in Hypertensive Emergencies (PHASE3)
- The Efficacy and Safety of Cleviprex in Ventriculostomy Patients Requiring IV Antihypertensive Therapy (PHASE4)
- The Effect of Clevidipine on Intracranial Pressure and Cerebral Perfusion Pressure (CCP) in Brain Injured Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Clevidipine butyrate CI brief — competitive landscape report
- Clevidipine butyrate updates RSS · CI watch RSS
- Methodist Healthcare portfolio CI